Vipul C. Chitalia, M.D., Ph.D.
Associate Professor
Boston University School of Medicine
Dept of Medicine
Nephrology

MD, Seth G.S. Medical College
MBBS, Lokmanya Tilak Medical College and Hospital
DM, Seth G.S. Medical College



Our laboratory focuses on the role of post-translational modifications of proteins, especially polyubiquitnation of the key mediators of vascular pathologies in diseases such as cancer and renal failure. While these diseases are discrete, several fundamental biological processes remain similar. Through a highly collaborative network, our laboratory harnesses the power of various cellular and molecular biological tools, relevant animal models (zebrafish and mice), computational methods and machine-learning techniques and strives to validate these findings and hypotheses in humanized models or human samples from large data bases, which highlights the translational nature of our approach.

A. Vascular diseases in kidney failure: Close to 20 million Americans or 10% of US population suffer from the chronic kidney disease (CKD). Among plethora of cardiovascular manifestations, CKD patients are particularly at high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation) in CKD patients. This area of CKD management warrants urgent investigation due to lack of risk predictors and CKD-specific therapeutic targets.
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity, and hence called uremic solutes/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes, which inhibits the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding into the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis) and to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.
Thrombosis being a dynamic and the multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM and established a Thrombosis and Hemostasis ARC, which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis. http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/

B. Angiogenesis: Angiogenesis, a process of generation of novel blood vessel is fundamental during the development and in various diseases such as cancer. Wnt signaling, a highly conserved oncogenic pathway is critical in angiogenesis. Beta catenin is the prime mediator of Wnt activation. Focusing on the ubiquitination and proteasomal degradation of beta catenin, our previous work had described Jade-1, as an E3 ligases of wild-type beta catenin. Our recent efforts have specifically focused on c-Cbl as an E3 ligase for the mutant beta catenin and for the transcriptionally active beta catenin in the nucleus. These two species of beta catenin, once considered resistant to degradation are effectively downregulated by c-Cbl. Thus, c-Cbl is a unique E3 ligase of tumorigenic beta catenin, which is involved in several cancers including colorectal cancer pathogenesis. Leveraging the cancer animal models and human cancer samples including machine learning based quantitative histology! techniques, our group investigates the colorectal cancer pathogenesis to gain deeper understanding of the role of E3 ligases of beta catenin E3 ligases in various cancers.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Active Staff Hospital Privileges
Boston Medical Center
Medicine



2016 Boston University : Outstanding Mentor award for UROP mentoring
2015-2017 Boston University School of Medicine: Evan’s Junior Faculty Merit Award
2007 Boston University School of Medicine: Annual Evan’s Research Day award
2005 Boston University School of Medicine: Annual Evan’s Research Day award
1998-1999 International Society of Nephrology: International Society of Nephrology Fellowship award
1995 University of Bombay: Gold medal Postdoctoral examination in Nephrology
1990-1992 University of Bombay: Merit Scholarship, Government of India
1987 University of Bombay: Charles Moorhead Prize



Thrombotic complication of uremia: role of prothrombotic uremic solutes
03/16/2016 - 02/28/2020 (PI)
NIH-NHLBI
5R01HL132325-02

Role of c-Cbi in Colon Cancer
07/01/2014 - 04/30/2019 (PI)
NIH-NCI
5R01CA175382-04

Role of Wnt Signaling in Uremia-induced Endothelial Dysfunction
06/14/2009 - 06/30/2014 (PI)
NIH-NIDDK
5K08 DK080946-04

Role of Wnt Signaling in uremia-induced endothelial dysfunction
07/01/2009 - 06/30/2013 (PI)
National Kidney Fdtn

Role of Jade-1 in Wnt Signaling
07/01/2006 - 06/30/2008 (PI)
Polycystic Kidney Disease Fdtn

Research Fellowship--Polycystic Kidney Disease
07/01/2003 - 06/30/2005 (PI)
National Kidney Fdtn



Yr Title Project-Sub Proj Pubs
2018 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-03
2018 Role of c-Cbl in Colon cancer 5R01CA175382-05
2017 Thrombotic complication of uremia: role of prothrombotic uremic solutes 5R01HL132325-02
2017 Role of c-Cbl in Colon cancer 5R01CA175382-04
2016 Thrombotic complication of uremia: role of prothrombotic uremic solutes 1R01HL132325-01
2016 Role of c-Cbl in Colon cancer 5R01CA175382-03
2015 Role of c-Cbl in Colon cancer 5R01CA175382-02
2014 Role of c-Cbl in Colon cancer 1R01CA175382-01A1
2013 Role of Wnt signaling in uremia-induced entothelial dysfunction 5K08DK080946-05 8
2012 Role of Wnt signaling in uremia-induced entothelial dysfunction 5K08DK080946-04 8
Showing 10 of 13 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Reddy YNV, Nunes D, Chitalia V, Gordon CE, Francis JM. Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents. Hemodial Int. 2018 Apr; 22 Suppl 1:S53-S60.View Related Profiles. PMID: 29694721.
     
  2. Kolachalama VB, Shashar M, Alousi F, Shivanna S, Rijal K, Belghasem ME, Walker J, Matsuura S, Chang GH, Gibson CM, Dember LM, Francis JM, Ravid K, Chitalia VC. Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans. J Am Soc Nephrol. 2018 Mar; 29(3):1063-1072.View Related Profiles. PMID: 29343519; DOI: 10.1681/ASN.2017080929;.
     
  3. Kolachalama VB, Singh P, Lin CQ, Mun D, Belghasem ME, Henderson JM, Francis JM, Salant DJ, Chitalia VC. Association of Pathological Fibrosis With Renal Survival Using Deep Neural Networks. Kidney Int Rep. 2018 Mar; 3(2):464-475.View Related Profiles. PMID: 29725651.
     
  4. Vijaya B. Kolachalama, Moshe Shashar, Faisal Alousi, Sowmya Shivanna, Keshab Rijal, Mostafa Belghasem, Joshua Walker, Shinobu Matsuura, C Michael Gibson, Laura M. Dember, Jean M. Francis, Katya Ravid, Vipul C. Chitalia. . Journal of American Association of Nephrology (in press) . Uremic solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Post-Vascular Injury Thrombosis in Humans . 2018; (March).
     
  5. Vijaya B. Kolachalama, Priyamvada Singh, Christopher Q. Lin, Dan Mun, Mostafa E. Belghasem, Joel M. Henderson, Jean M. Francis, David J. Salant and Vipul C. Chitalia. . Association of Pathological Fibrosis With Renal Survival Using Deep Neural Networks. Kidney International Reports 2018 (in press). 2018.
     
  6. Shashar M, Belghasem ME, Matsuura S, Walker J, Richards S, Alousi F, Rijal K, Kolachalama VB, Balcells M, Odagi M, Nagasawa K, Henderson JM, Gautam A, Rushmore R, Francis J, Kirchhofer D, Kolandaivelu K, Sherr DH, Edelman ER, Ravid K, Chitalia VC. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci Transl Med. 2017 Nov 22; 9(417).View Related Profiles. PMID: 29167396; DOI: 10.1126/scitranslmed.aam8475;.
     
  7. Woolf N, Pearson BE, Bondzie PA, Meyer RD, Lavaei M, Belkina AC, Chitalia V, Rahimi N. Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy. Oncogenesis. 2017 Sep 18; 6(9):e378.View Related Profiles. PMID: 28920928; DOI: 10.1038/oncsis.2017.77;.
     
  8. Al-Rabadi L, Quillen K, Shashar M, Al Marji C, Jaberi A, Chitalia V, Henderson J, Salant D, Beck LH. Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. Kidney Int Rep. 2018 Mar; 3(2):476-481.View Related Profiles. PMID: 29725652.
     
  9. Zhang A, Rijal K, Ng SK, Ravid K, Chitalia V. A mass spectrometric method for quantification of tryptophan-derived uremic solutes in human serum. J Biol Methods. 2017; 4(3).View Related Profiles. PMID: 29707597.
     
  10. Abraham E, Gadish O, Franses JW, Chitalia VC, Artzi N, Edelman ER. Matrix-Embedded Endothelial Cells Attain a Progenitor-Like Phenotype. Adv Biosyst. 2017 Sep; 1(9). PMID: 29862313.
     
Showing 10 of 50 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 43 publications over 16 distinct years, with a maximum of 9 publications in 2017

YearPublications
19941
19981
19991
20012
20021
20051
20082
20101
20112
20122
20133
20146
20155
20161
20179
20185
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Chronic Kidney Disease
E3 Ubiquitin Ligase
Thrombosis
Uremic Vascular Disease
Wnt Signaling

I am an Assistant Professor of Medicine at Boston University School of Medicine and an affiliate of Biomedical Engineering at Harvard-MIT Division of Science and Technology, MIT. I am also an attending nephrologist covering renal consults and dialysis and kidney transplant in-patients services at Boston Medical Center. Teaching is my passion and I consider it as my honor to be able to contribute in the training of next generation of physicians, scientists and physician-scientists. I strongly believe that a true mentor is one who inspires passion from within and empowers a mentee to find his or her own path of success. Spanning over entire spectrum, our laboratory has trained several undergraduate students, graduate students and post doctoral fellows, of which several are clinical fellows from renal, cardiovascular and hematology-oncology specialties. Our laboratory has not only US researchers, but has students and post doctoral fellows from Europe, Middle East and Asia creating a truly international learning environment. I have been awarded 2016 Outstanding Mentor Award from the undergraduate research opportunity program (UROP) of Boston University and been nominated for best research mentoring award at BUSM.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Chitalia's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department